StockData
Renalytix plc logo

Renalytix plc (RNLXY) stock

RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF
Financials through Q1 FY2025, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$3.56+0.06 (+1.57%)

Close on Oct 19, 2026Market cap $375.75MP/E –Yield –

Renalytix r&d expenses

Research and development expenses are spending on new products and technology.

Renalytix's R&D Expenses for the twelve months ending Sep 30, 2024 was $7.42M, down 44.3% year over year. For fiscal 2024 it was $9.29M, down 35.0% from the year before. The highest annual figure on record is $14.65M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2024Jun 30, 2024$9.29M-35.0%
FY2023Jun 30, 2023$14.30M-2.4%
FY2022Jun 30, 2022$14.65M+45.9%
FY2021Jun 30, 2021$10.04M+119.9%
FY2020Jun 30, 2020$4.57M+5.8%
FY2019Jun 30, 2019$4.32M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2025CQ3 2024Sep 30, 2024$921.00K-67.0%
Q4 FY2024CQ2 2024Jun 30, 2024$1.06M-67.5%
Q3 FY2024CQ1 2024Mar 31, 2024$2.22M-43.8%
Q2 FY2024CQ4 2023Dec 31, 2023$3.23M-3.0%
Q1 FY2024CQ3 2023Sep 30, 2023$2.79M-25.8%
Q4 FY2023CQ2 2023Jun 30, 2023$3.27M+24.5%
Q3 FY2023CQ1 2023Mar 31, 2023$3.94M+1.4%
Q2 FY2023CQ4 2022Dec 31, 2022$3.33M-19.5%
Q1 FY2023CQ3 2022Sep 30, 2022$3.76M-6.0%
Q4 FY2022CQ2 2022Jun 30, 2022$2.63M-3.7%
Q3 FY2022CQ1 2022Mar 31, 2022$3.89M+25.2%
Q2 FY2022CQ4 2021Dec 31, 2021$4.13M+67.9%
Q1 FY2022CQ3 2021Sep 30, 2021$4.00M–
Q4 FY2021CQ2 2021Jun 30, 2021$2.73M–
Q3 FY2021CQ1 2021Mar 31, 2021$3.10M–
Q2 FY2021CQ4 2020Dec 31, 2020$2.46M–

More Renalytix figures

See a number that looks wrong?